Pharmacogenetic Effect of the Stromelysin (MMP3) Polymorphism on Stroke Risk in Relation to Antihypertensive Treatment: The Genetics of Hypertension Associated Treatment Study

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Stroke

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/STROKEAHA.110.593798PMID 21183746PMCID PMC3859235
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blood Pressure Control by Drug Group in the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

  2008cited by this paper
• The lifetime risk of stroke: estimates from the Framingham Study.

  2006cited by this paper
• Current Concepts of Cerebrovascular Disease and Stroke Carotid Plaque Morphology and Risk for Stroke

  2005cited by this paper
• Evaluating bias due to population stratification in case‐control association studies of admixed populations

  2004cited by this paper
• Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese.

  2003cited by this paper
• Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction.

  2003cited by this paper
• Matrix Metalloproteinase‐3 Genotype Contributes to Age‐Related Aortic Stiffening Through Modulation of Gene and Protein Expression

  2003cited by this paper
• The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.

  2003cited by this paper
• Matrix Metalloproteinase-1 and Matrix Metalloproteinase-3 Gene Promoter Polymorphisms Are Associated With Carotid Artery Stenosis

  2002cited by this paper
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

  2002cited by this paper
• Carotid Intima-Media Thickness Is Associated With Allelic Variants of Stromelysin-1, Interleukin-6, and Hepatic Lipase Genes: The Northern Manhattan Prospective Cohort Study

  2002cited by this paper
• Large Artery Stiffness: Structural And Genetic Aspects

  2001cited by this paper
• Stromelysin-1 and Interleukin-6 Gene Promoter Polymorphisms Are Determinants of Asymptomatic Carotid Artery Atherosclerosis

  2000cited by this paper
• Inflammatory Mediators and Stroke: New Opportunities for Novel Therapeutics

  1999cited by this paper
• Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction.

  1999cited by this paper
• Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis.

  1999cited by this paper
• A multilocus genotyping assay for candidate markers of cardiovascular disease risk.

  1999cited by this paper
• The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial.

  1998cited by this paper
• Progression of Coronary Atherosclerosis Is Associated with a Common Genetic Variant of the Human Stromelysin-1 Promoter Which Results in Reduced Gene Expression*

  1996cited by this paper
• Hypertension and stroke

  1996cited by this paper
• Ischemic stroke events and carotid atherosclerosis. Results of the Osaka Follow-up Study for Ultrasonographic Assessment of Carotid Atherosclerosis (the OSACA Study).

  1995cited by this paper
• Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.

  1994cited by this paper
• Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis.

  1994cited by this paper
• Parallel Cardiac and Vascular Adaptation in Hypertension

  1992cited by this paper
• Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization.

  1991cited by this paper
• Hypertension and stroke.

  1984cited by this paper
• The natural history of carotid arterial disease in asymptomatic patients with cervical bruits.

  1984cited by this paper
• Collagenolytic enzymes and their naturally occurring inhibitors.

  1981cited by this paper

• Exploring Cytokine Networks in Resistant Hypertension

  2023cites this paper
• Pharmacogenetic association of the NR1H3 promoter variant with antihypertensive response among patients with hypertension: A longitudinal study

  2023cites this paper
• [The role of gene-gene and gene-environmental interactions of polymorphic matrix metalloproteinases loci in the formation of the risk of stroke in men with hypertension].

  2022cites this paper
• Compound Danshen Dripping Pill inhibits doxorubicin or isoproterenol-induced cardiotoxicity.

  2021cites this paper
• Association Between Stress and Coping with DNA Methylation of Blood Pressure-Related Genes Among African American Women

  2019cites this paper
• [The role of stress factors and genetic predisposition in the development of stroke in patients with essential hypertension].

  2019cites this paper
• The Role of the Stress Factor in Mediating the Genetic Predisposition to Stroke of the Background of Hypertensive Disease

  2019cites this paper
• MMP 3-1171 5 A / 6 A Promoter Polymorphism Affects Level of Serum Major Histocompatibility Complex Class Chain Related B in Breast Cancer Patients

  2018cites this paper
• Association of matrix metalloproteinase-3 gene 5A/6A polymorphism with the recurrence of ischemic stroke: A prospective observational study.

  2017cites this paper
• MMP3 -1171 5A/6A Promoter Polymorphism Affects Level of Serum Major Histocompatibility Complex Class Chain Related B in Breast Cancer Patients

  2017cites this paper
• The Intergenerational Impact of Genetic and Psychological Factors on Blood Pressure (InterGEN) Study

  2016cites this paper
• A Physiologic Approach to the Pharmacogenomics of Hypertension.

  2016cites this paper
• Hypertension pharmacogenomics: in search of personalized treatment approaches

  2016cites this paper
• The effects of genes implicated in cardiovascular disease on blood-pressure response to treatment among treatment-naïve hypertensive African Americans in the GenHAT study

  2015cites this paper
• The effect of gender and genetic polymorphisms on matrix metalloprotease (MMP) and tissue inhibitor (TIMP) plasma levels in different infectious and non‐infectious conditions

  2015cites this paper
• Impact of matrix metalloproteinases on atherosclerosis.

  2014cites this paper
• Proteome‐wide analysis of nonsynonymous single‐nucleotide variations in active sites of human proteins

  2013cites this paper
• Drug Interactions, Pharmacogenomics and Cardiovascular Complication

  2013cites this paper
• Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT

  2013cites this paper
• Exposure to environmental tobacco smoke, human E-cadherin C-160A polymorphism, and childhood asthma.

  2013cites this paper
• Advancing management of hypertension through pharmacogenomics

  2012cites this paper
• Pharmacogenomic approaches to study the effects of antihypertensive drugs

  2012cites this paper
• Pharmacogenetics in randomized controlled trials: considerations for trial design.

  2011cites this paper
• Mutational analysis of the Kir6.1 gene in Chinese hypertensive patients treated with the novel ATP-sensitive potassium channel opener iptakalim.

  2011cites this paper
• Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

  2011cites this paper
• Association of the antihypertensive response of iptakalim with KCNJ11 (Kir6.2 gene) polymorphisms in Chinese Han hypertensive patients

  2011cites this paper
• Cardiovascular pharmacogenomics.

  2011cites this paper
• [Cardiovascular pharmacogenomics].

  2009cites this paper
• International Journal of Molecular Sciences the Role of Matrix Metalloproteinase Polymorphisms in Ischemic Stroke

  year unknowncites this paper